A cross-sectional study to estimate the point prevalence of painful diabetic neuropathy in Eastern Libya. by Garoushi, S et al.
RESEARCH ARTICLE Open Access
A cross-sectional study to estimate the
point prevalence of painful diabetic
neuropathy in Eastern Libya
Sabri Garoushi1,2,3* , Mark I. Johnson1,2 and Osama A. Tashani1,2,3
Abstract
Background: Painful Diabetic Neuropathy (PDN) is a complication that affects up to one third of people living with
diabetes. There is limited data on the prevalence of PDN from countries in the Middle East and North Africa. The
aim of this study was to estimate the point prevalence of PDN in adults in Eastern Libya using the self-report Leeds
Assessment of Neuropathic Symptoms and Signs (S-LANSS) pain scale.
Methods: We invited patients attending the Benghazi Diabetes Centre who had diabetes for ≥ 5 years to take part
in the study. Patients provided consent and completed the Arabic S-LANSS. Anthropometrics, marital status,
socioeconomic and education information was recoded and fasting plasma glucose concentration determined.
Results: Four hundred and fifty participants completed the study (age = 19 to 87 years, BMI = 17.6 to 44.2 kg/m2,
224 women). One hundred and ninety five participants (43.3%) reported pain in their lower limbs in the previous
6 months and 190/195 participants (97.4%) reported a S-LANSS score of ≥ 12 suggesting they had neuropathic
pain characteristics. Thus, 42.2% (190/450) of participants with diabetes were categorised as experiencing pain
with neuropathic characteristics. Mean ± SD duration of diabetes for participants with PDN (20.4 ± 6.5 years) was
significantly higher compared with those without PDN (11.1 ± 4.6 years). Participants with PDN smoked tobacco for
more years than those without pain (7.9 ± 12.3 years versus 1.1 ± 3.9 years respectively); had significantly higher
fasting plasma glucose concentration (143.6 ± 29.3 mg/dl versus 120.0 ± 17.3 mg/dl) and had a significantly higher
levels of education and employment status. The most significant predictors of PDN were duration of diabetes
(OR = 25.85, 95% CI = 13.56–49.31), followed by smoking for men (OR = 8.28, 95% CI = 3.53–9.42), obesity (OR = 3.96,
95% CI = 2.25–6.96) and high fasting plasma glucose concentration (OR = 3.51, 95% CI = 1.99–6.21).
Conclusion: The prevalence of PDN in people with diabetes in Eastern Libya was 42.2%. Risk factors for developing
PDN were high fasting plasma glucose concentration, long duration of diabetes, and higher level of educational
and employment status.
Background
Diabetes is a global health care problem and financially
costly. The cost of treating complications arising from
diabetes is 3 to 4 times more than the cost treating dia-
betes. Data about the financial cost and burden of dia-
betes on resource-limited countries is lacking, with few
estimates of prevalence of the disease or its
complications. It has been estimated that the point preva-
lence of diabetes in the Middle East and North Africa
(MENA) in 2017 was 38.7 million (11% of the population)
[1, 2]. In 2017, the International Diabetes Federation (IDF)
estimated that the total financial health care costs of treat-
ing diabetes and its complications in the MENA region
was equivalent to £15.45 billion GBP ($20.5 billion USD).
This equates to 15% of total health costs and higher than
the World as a whole (11.3%), Europe (10%) and Africa
(5.7%) [2]. Projections suggest that the incidence of dia-
betes in the MENA region will double by 2045 and finan-
cial costs will rise to £28 billion GBP ($37 billion USD) by
2045 [2].
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Painful Diabetic Neuropathy (PDN) is a common com-
plication of diabetes affecting up to one third of patients
worldwide. Diagnosis, treatment and management of
PDN can be challenging for clinicians because of the com-
plexity of pathophysiological mechanisms contributing to
pain [3, 4]. Tools that capture a person’s self-report of their
pain experience are available to assist clinicians screen for
the presence of probable neuropathic pain [5]. Examples
include: The Leeds Assessment of Neuropathic Symptoms
and Signs (LANSS) [6]; the Neuropathic Pain Question-
naire (NPQ) [7]; Douleur Neuropathique en 4 questions
(DN4) [8]; painDETECT [9]; ID-Pain [10] and the Stan-
dardized Evaluation of Pain (StEP) [11]. Management of
PDN in the MENA region appears to be inadequate with
limited use of neuropathic screening tools and a paucity of
data on the extent of the problem, especially in the Magh-
reb area (Libya, Tunisia, Algeria and Morocco) [12]. The
prevalence of PDN in people with diabetes has been esti-
mated to be 53.7% in the Middle East region [13], 65.3% in
Saudi Arabia [14] and 14% in Turkey [15]. Recently, we
conducted a systematic review that included eight sur-
veys of seven countries from the MENA region (Saudi
Arabia, Algeria, Egypt, Lebanon, Jordan, Gulf States
and Turkey) [16] and estimated the point prevalence of
PDN associated with type 1 or type 2 diabetes to be
43.2% (95% CI = 30.1–57.2%, pooled sample = 7898
adults (3761 women), effect size = − 0.949).
In 2017, the IDF predicted that 442,500 people were
living with diabetes in Libya (11.2% of the population)
[17]. In 2012, Elzahaf et al. [18] published the findings of
a systematic review of data from 65 surveys in 34 coun-
tries that estimated the prevalence of chronic pain
worldwide to be 30.3% ± 11.7%, although they failed to
identify any data for Libya. Recently, we conducted a
search of research databases and failed to find any epi-
demiological studies estimating the prevalence of PDN
in Libya. Previously we have translated the LANSS pain
scale and the self-report version of the Leeds Assess-
ment of Neuropathic Symptoms and Signs (S-LANSS)
into Arabic and found both instruments to be valid and
reliable to screen for neuropathic pain in a sample of
adults with diabetes living in Libya [19]. We estimated
the prevalence of PDN to be 41.3%, but expressed cau-
tion at this finding because it was derived from a small
sample of 109 adult patients. The aim of the present
cross-sectional epidemiological study was to estimate
the point prevalence of PDN using a larger sample in
adults from Eastern Libya and to determine risk factors
that contribute to development of the condition.
Methods
Study design
This was a cross-sectional study that collected S-LANSS
scores and indices of glycaemic control from a sample of
patients with diabetes attending the Benghazi Diabetes
Centre (BDC), Libya. The BDC has been operational for
48 years and is one of the largest diabetes centres in Libya,
servicing the Eastern region of the country. The Centre
employs 25 health care professionals, including five physi-
cians dedicated to patient follow-up, with between 300
and 500 consultations each day and a throughput of ap-
proximately 100,000 patients per year [20, 21]. Services in-
clude reviewing patients’ medication, measuring fasting
plasma glucose concentration, checking for complications
of diabetes and referral to follow-up clinics for endocrine
care, eye care, dental care and diet. There is no follow-up
service for painful nor non-painful diabetic neuropathy
and limited provision for foot care to prevent gangrene.
Ethical approval to conduct the study was granted
from Leeds Beckett University research ethics commit-
tee and study-site permission from Benghazi Health
Authority. The well-being, privacy, dignity and safety of
participants were respected at all times in accordance
with the Research Governance Framework and Policy
and Practice of Research Ethics of Leeds Beckett
University, and Medico-legal principles approved by the
Libyan General Medical Council.
Sample population and sample size
The sample size was calculated using an online calcula-
tor (Soft Stat software) based on the minimum sample
size needed to estimate the true population proportion
with the required margin of error of 0.05% and confi-
dence level at 95%. A sample of 400 participants was re-
quired to detect a relationship between the duration of
diabetes (independent variable) and S-LANSS score
(Arabic version, dependent variable). The level of statis-
tical significance was set at 0.05 (two-sided). A target
sample of 450 participants was set to account for attri-
tion due, for example, to withdrawal of participants, with
equal numbers of men and women matched for age into
five subgroups: 18 < 30 years, 30 < 40 years, 40 < 50 years,
50 < 60 years and ≥ 60 years.
Receptionists and health care team members from the
BDC advertised the study verbally. Potential participants
were contacted in liaison with the BDC and an informa-
tion form was distributed. Patients expressing interest in
the study were given a participant information pack and
were contacted 48 h later to be invited to attend one,
one-hour study visit. The process of invitation, selection,
inclusion/exclusion and enrolment is described in the
study flow chart (Additional file 1).
Study visit
All eligible volunteers were enrolled onto the study by
providing signed consent. Participants were interviewed by
the Principal Investigator (SG) and provided data on
anthropometrics, socioeconomics and education. If
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participants answered ‘yes’ to the question “Have you suf-
fered from any pain in your feet in the last 6 months?” they
were invited to complete the Arabic version of the
S-LANSS pain scale. A fasting sample of venous blood was
collected by a trained member of staff from the BDC.
Data management and analysis
Data was analysed using Statistical Package for Social Sci-
ence (SPSS) version 22. Data is described as mean and
standard deviation unless otherwise stated. Distribution of
continuous variables were tested for normality using the
kolmogrov-Smirnov statistic. Comparison between two
continuous variables (e.g. duration of diabetes of men
versus women) were examined using an unpaired t-test if
the distribution of the variable was normal, and a Mann-
Whitney statistic if the distribution was not normal. Dif-
ferences between two proportions or two dichotomous
variables were tested statistically using Chi-square or Z
tests.
Initially, we calculated crude odd ratios of having PDN
for groups of participants classified according to; sex, age
group, Body Mass Index (BMI), duration of diabetes, fast-
ing plasma glucose concentration and smoking for men
only, as all women were non-smokers. The assignment of
a reference group in all odds ratio calculations was based
on previous literature to allow for meaningful compari-
sons [22]. We used a logistic regression model to test
whether potential risk factors (sex, age, BMI, smoking
history for men, duration of diabetes and fasting plasma
glucose concentration) predicted probable neuropathic
pain (i.e. a total S-LANSS score of ≥ 12). We chose logistic
regression because the outcome variable was dichotomous
and it would be possible to calculate adjusted odds ratios
for all potential predictors. Each independent variable in
the model had two categories (e.g. age = ≤ 60 years
and > 60 years (old age); BMI = < 30 Kg/m2and ≥ 30
Kg/m2 (obese); duration of diabetes = 5–15 years and > 15
years; and fasting plasma glucose concentration ≤ 125mg/
dl and > 125mg/dl). In addition, the association between
potential risk factors (i.e. collinearity) was tested using the
Spearman correlation coefficient [23].
Results
Characteristics of the sample
In total, 549 volunteers were invited to attend a study visit,
of which 99 declined for a variety of reasons, often be-
cause they were ‘too busy’ or it was ‘too far to travel’. Four
hundred and fifty volunteers attended a study visit and all
completed the study protocol (age = 19–87 years, BMI =
17.6–44.2 kg/m2, 224 women, Table 1). Nine samples of
Table 1 Characteristics of participants
Characteristic Men Women Total P value*
Sample size 226 224 450
Age (years) 49.17 ± 13.99 51.96 ± 13.67 50.56 ± 13.89 0.03a
BMI (kg/m2) 29.77 ± 3.80 29.23 ± 4.70 29.50 ± 4.28 0.18a
Plasma glucose**(mg/dl) 131.77 ± 25.95 128.93 ± 26.18 130.35 ± 26.08 0.17b
Duration of Diabetes (years) 15.40 ± 7.08 14.75 ± 7.18 15.08 ± 7.13 0.26b
Smoking (n, %) 93, 41.2% 0% 20.7% 0.00c
Duration of smoking (years) 7.99 ± 11.71 No women smokers 7.99 ± 11.71*** 0.00b
Employment (n, %) 173, 76.5% 126, 56.3% 299, 66.4% 0.00c
Education (n, %)
• Cannot read or write 42, 18.6% 50, 22.3% 92, 20% 0.66 c
• Can read and write**** 19, 8.4% 36, 16.1% 55, 12.2% 0.43 c
• Primary 30, 13.3% 28, 12.5% 58, 12.9% 0.93 c
• Secondary 40, 17.7% 32, 14.3% 72, 16% 0.70 c
• University or above 95, 42% 78, 34% 173, 38.4% 0.27 c
Marital status (n, %)
• Married (no children) 37, 16.4% 28, 12.5% 65, 14.4% 0.66 c
• Married (children) 139, 61.5% 142, 63.4% 281, 62.4% 0.74 c
• Unmarried 30, 13.3% 27, 21.1% 57, 12.7% 0.44 c
• Others 20, 8.8% 27, 12.1% 47, 10.4% 0.72 c
*Differences between mean ± SD or the proportions of men and women were tested by a unpaired t-test, if the data was normally distributed, b Manny Whitney if
the data was not normally distributed and c Chi square to test the differences in between proportions of men and women
**Plasma glucose numbers are 221 for males and 220 for females
***None of the women were smokers, so there is no mean or standard deviation for this group. Values for males only
****can read and write but not formally educated
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blood were not obtained from participants and recorded
as missing data. Women were older than men (mean
difference = − 2.79 years, 95% CI = − 5.35-0.23 years), but
there was no difference in BMI between women and men
(mean difference = 0.55 kg/m2, 95% CI = − 0.25-1.33 kg/m2).
Mean ± SD fasting plasma glucose concentration was
130.35 ± 26.08 mg/dl (n = 441 participants) and mean ±
SD duration of diabetes was 15.08 ± 7.13 years. There
were no differences between women and men in fasting
plasma glucose concentration (mean difference = 2.85mg/
dl, 95% CI = − 2.03-7.73mg/dl) or duration of diabetes
(mean difference = 0.64 years, 95% CI = − 0.68-1.97 years).
There were 93 smokers (41.2%) and all were men. Fewer
women were employed than men.
Two hundred and twenty six participants (50.2%) used
insulin on its own for diabetes control. One hundred and
sixty three participants (36.2%) used oral hypoglycaemic
medications on their own and 61 participants (13.6%)
used a combination of insulin and oral hypoglycaemic
medication. Fig. 1 presents complications associated with
diabetes.
One hundred and ninety five participants answered
‘yes’ to having suffered from pain in the foot in the last
six months. Thirty seven of these 195 participants
(19%) received over the counter medications (OTCs)
without specifying names. Thirty three participants (17%)
received paracetamol (PCM), 27 participants (13.8%) re-
ceived PCM and non-steroidal anti-inflammatory drugs
(NSAIDs), 22 participants (11.9%) received tramadol, 22
participants (10.7%) received co-codamol, 19 participants
(9.7%) received NSAIDs, 13 participants (6.7%) received
codeine, eight participants (4.1%) received herbal medi-
cine, 5 participants (2.6%) received cupping, four partici-
pants (2%) received gabapentin and three participants
(1.5%) received duloxetine. Three participants reported re-
ceiving no treatment at all (1.5%).
Prevalence of pain with neuropathic characteristics
Of the 450 participants in our sample, 195 (43.3%) re-
ported pain in the previous 6months. All of these partici-
pants reported that this pain was in their lower limbs. Of
the 195 participants reporting pain, 190 scored ≥ 12 on
S-LANSS. Thus, 42.2% (190/450) of participants with dia-
betes were categorised as experiencing pain with neuro-
pathic characteristics. Interestingly, only seven of the 195
(3.6%) participants with pain reported that they had been
clinically diagnosed with painful diabetic neuropathy.
There was no statistically significant differences in the
prevalence of pain with neuropathic characteristics be-
tween women and men (odds ratio (OR) = 0.97, 95% CI
= 0.67–1.4). Risk factors for the development of PDN
were more than 60 years of age (OR = 1.93, 95% CI =
1.22–3.04), longer duration of diabetes (OR = 23.41, 95%
CI = 14.26–38.46), had smoked tobacco for more years
(OR = 5.60, 95% CI = 3.11–8.60), had higher fasting
plasma glucose levels (OR = 3.11, 95% CI = 2.1–4.6), had
higher BMI (OR = 4.56, 95% CI = 3.1–6.8) and had
higher employment status.
Multivariate (adjusted) odd ratio
The adjusted odds ratios in the multivariate logistic re-
gression model (Table 2) revealed that the most signifi-
cant predictors of PDN were duration of diabetes (OR
= 25.85, 95% CI = 13.56–49.31), followed by smoking in
men (OR = 8.28, 95% CI = 3.53–9.42), obesity (OR =
3.96, 95% CI = 2.25–6.96) and high fasting plasma glu-
cose concentration (OR = 3.51, 95% CI = 1.99–6.21).
The effect of sex and age was not significant on the
prevalence of PDN (OR sex = 0.24, 95% CI = 0.17–0.48;
OR age = 0.54, 95% CI = 0.3–1.1).
Discussion
This study estimated that 42.2% of individuals with dia-
betes in Eastern Libya had probable PDN, based on a
S-LANSS score of ≥12. This estimate is similar to our
pilot study that found that 41.3% of 109 individuals with
diabetes had probable PDN [19]. The estimate is similar
to the findings of our systematic review that estimated
the prevalence of PDN in individuals with diabetes in
the MENA region to be 43.2%, (95% CI = 30.1–57.2%,
eight surveys, 7806 participants, 3761 women) [16]. Our
estimate of prevalence of PDN in Libya is lower than
that reported in Saudi Arabia (65.3%) [14] and higher
than Turkey (14%) [15] and (23%) [24], but higher than
the UK (33%) [25] and the United States of America
USA (11–25%) [26].
Reasons for the differences in estimates between
countries
There are variations in the estimates of the prevalence of
PDN between and within countries in research literature.
Reasons include disparities in study methodologies, sam-
ple characteristics, eligibility criteria for co-morbidities,
treatments to manage diabetes and operational definitions
and measurement techniques to identify neuropathic pain
[27–29]. For example, a cross-sectional study conducted
in the UK using a postal survey estimated that 64% of in-
dividuals with diabetes experienced neuropathic elements
but this figure declined to 30% when these respondents
were assessed using a neurological examination [27].
There has been a debate about the possibility of imprecise
estimates of prevalence due to the use of neuropathic
pain screening tools rather than full neurological exam-
ination [30–33]. Symptoms-based questionnaires includ-
ing S-LANSS are widely used to screen for probable
neuropathic characteristics by researchers and health care
professionals prior to further examination if required.
Thus, we decided to use the S-LANSS as it would enable
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direct comparison with previous studies. We intend to
conduct a study using full neurological examination in the
future [33].
Risk factors for the development of PDN
The main risk factors for PDN identified in our study
were increased duration of diabetes (> 15 years), obesity
(BMI ≥ 30 Kg/m2), high fasting plasma glucose concen-
tration (> 125 mg/dl) and smoking (only for men). This
is consistent with research findings from other studies
in the MENA region [12–15, 24, 34, 35] and worldwide
[36]. Other risk factors not measured in our study in-
clude hypertension and high cholesterol. Evidence also
suggests that there is a higher incidence PDN in indi-
viduals with prolonged impaired glucose intolerance
before diabetes has been diagnosed [37–39]. Socioeco-
nomic factors including lifestyle, diet, and health care
policies such as food labelling and the availability low
glycaemic food items facilitating blood sugar level con-
trol contribute to higher incidence of diabetes and
associated complications and may be one reason for
country and regional differences in the prevalence of
PDN [29].
Higher levels of education and employment were also
associated with higher percentages of people with PDN
possibly because they are more likely to have sedentary
jobs and higher BMI.
Clinical implications of the findings
In our study, only 3.6% of individuals with PDN re-
ported that they had received a diagnosis of PDN from
their clinician and this was from consultations outside
of Libya (Tunisia and Egypt). We speculate that clini-
cians in Libya may not be aware of the presence of
PDN in patients or that they consider PDN to be an in-
evitable consequence of diabetes and not worthy of spe-
cific consideration and/or treatment. Clearly, there is a
need to raise awareness of the importance of diagnosing
and managing PDN including the consequence of inad-
equate control of diabetes in future policy. Our findings
provide evidence that long-term glycaemic control is
critical to reduce the incidence of PDN and that there
is inadequate management of pain. This is not unique
to Libya. For example, Daousi et al. reported that PDN
was inadequately managed in more than 40% of indi-
viduals in the United Kingdom [29, 40], with similar
findings in Canadian populations [41].
Strong evidence from systematic reviews suggest that
PDN can be managed using pharmacological interven-
tions including tricyclic antidepressants and gabapentin
or pregabalin as first-line treatments and serotonin-
norepinephrine reuptake inhibitors or opioids as second-
line treatments [3, 12]. This approach has been endorsed
by professional bodies, including the International Associ-
ation for the Study of Pain (IASP) and the National
Institute for health and Care Excellence (NICE) and has
Table 2 Crude and adjusted odd ratios for the potential risk factors of PDN in Eastern Libya
Predictor binary variables PDN
Present
PDN
Absent
Odds ratio
(95% CI, P value)
Adjusted odds ratio
(95% CI, P value)
Sex
Mena 96 128 0.97 0.24
Women 95 131 (0.67 to 1.4, 0.86) (0.17 to 0.48, 0.89)
Age
≤ 60 yearsa 138 126 1.93 0.54
> 60 years 53 43 (1.22 to 3.04, 0.005) (0.26 to 1.1, 0.89)
BMI
< 30 Kg/m2 a 66 183 4.56 3.96
≥ 30 Kg/m2 125 76 (3.1 to 6.8, < 0.0001) (2.25 to 6.96, < 0.0001)
Smoking
Non-smokersa 68 25 5.60 8.28
Smokers 123 234 (3.11 to 8.60, < 0.0001) (3.53 to 19.42, < 0.0001)
Duration of diabetes
5–15 yearsa 41 224 23.41 25.85
> 15 years 150 35 (14.26 to 38.46, < 0.0001) (13.56 to 49.31, < 0.0001)
Fasting blood sugar
≤ 125mg/dla 65 155 3.11 3.51
> 125mg/dl 125 96 (2.1 to 4.6, < 0.0001) (1.99 to 6.21, < 0.0001)
aReference group
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been adapted for use in the MENA region [12, 42]. How-
ever, treatments received by participants in our sample
suggest that this approach was not implemented, with
only four participants receiving a first-line drug (gaba-
pentin) and 53 a second-line drug (either tramadol,
co-codamol or codeine). Of the remaining participants
who received treatment for their pain, some received
analgesics not suitable for the neuropathic pain or al-
ternative therapies such as herbal medicine or cupping.
Strengths and shortcomings of the study
This is the first attempt to estimate the prevalence of
PDN in individuals living in Libya using an appropriately
powered study with adequate sample size. The absence of
diagnosis based on a full neurological examination is a
limiting factor, although we estimated that the use of our
validated Arabic version of the S-LANSS pain scale would
identify at least 75% of individuals with PDN [43]. We
measured fasting plasma glucose concentration rather
than haemoglobin A1c (HbA1c) which is a more robust
indicator of blood sugar control. We did not measure
blood pressure, triglycerides and cholesterol levels and
such data would have enabled determination of their role
as probable risk factors.
The sample may be subject to selection bias because the
study site clinic only services the Eastern region of Libya.
However, there are no primary services for individuals
with diabetes in Libya so individuals have to attend re-
gional specialised clinics. Thus, the sample is likely to have
captured all people with diabetes who were willing and
able to attend the clinic. Nevertheless, we express caution
in the generalisability of our estimate because of the use of
a single-site and the impact of unmeasurable confounders.
Future directions
It is hope that our findings will be used to inform future
policy for the diagnosis and management of PDN associ-
ated with diabetes in Libya, including the creation of a na-
tional prevention program [44]. Future epidemiological
research is needed from resource limited countries to
provide a more a balanced picture of the problem of PDN
globally. There is an increasing focus on epigenetics to
identify individuals susceptible to PDN [45], and studies
investigating the incidence of microvascular pathology
preceding diagnosis of diabetes would provide valuable in-
sights into the pathogenesis of PDN. Microvascular path-
ology is known to contribute to neuropathy and may have
clinical utility as a predictor of PDN.
Conclusion
The prevalence of PDN in adults with diabetes in Eastern
Libya was 42.2% and risk factors for developing PDN
were high blood glucose, long duration of diabetes, and
higher level of educational and employment status. The
prevalence of PDN in Libya is higher than reported in
countries in Europe and the USA. We suspect that
some clinicians in Libya may consider PDN to be an in-
evitable consequence of diabetic neuropathy and fail to
appreciate the importance of appropriate management.
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